impassion130 data demonstrate clinical benefit for immunotherapy in metastatic tnbc
Published 5 years ago • 153 plays • Length 0:59Download video MP4
Download video MP3
Similar videos
-
6:33
case 3: results of the impassion130 trial in metastatic breast cancer
-
2:51
impassion130: design and preliminary efficacy
-
2:30
impassion130: immunotherapy for tnbc
-
7:19
impassion130 trial: os updates in metastatic tnbc
-
6:56
impassion130 trial data on pd-l1 tumors in tnbc
-
6:54
impassion130 trial data on pd-l1 tumors in tnbc
-
1:38
treatments under investigation for metastatic tnbc
-
2:20
systemic therapy for recurrent metastatic tnbc
-
3:33
eribulin in metastatic tnbc: real-world data
-
5:40
case 4: looking forward in brca metastatic tnbc
-
1:40
treatment of metastatic triple-negative breast cancer
-
0:51
challenges in the treatment of mtnbc
-
2:52
impassion130 study: improvement in os and pfs for iit and pd-l1 populations with mtnbc
-
7:40
study of carboplatin plus nivolumab in metastatic triple-negative breast cancer
-
3:05
esmo 2020 highlights on sacituzumab govitecan in metastatic tnbc: the ascent study
-
2:33
applying impassion130 data to tnbc management
-
1:55
sara m. tolaney, md, mph, shares outcomes from the impassion130 study in tnbc
-
1:07
phase ii results for pembrolizumab monotherapy in metastatic tnbc
-
1:00
overcoming challenges in treating patients with triple-negative breast cancer